Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 7/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL512865 | 0.86 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL16914028 | 0.82 | TLR2 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1616767 | 0.80 | ALDH1A1 (0.49) | TLR2TLR1LMNAKMT2AL3MBTL1 | |
| SCHEMBL8475128 | 0.79 | ALDH1A1 (0.50) | TLR2TLR1LMNAKMT2AALDH1A1 | |
| SCHEMBL10914480 | 0.79 | CYP19A1 (0.51) | CYP19A1LMNAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL8034073 | 0.78 | TLR2 (0.49) | TLR2TLR1ALDH1A1HTT | |
| SCHEMBL1038671 | 0.78 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1617550 | 0.78 | ALDH1A1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1616714 | 0.78 | ALDH1A1 (0.47) | TLR2TLR1LMNAKMT2AALDH1A1 | |
| SCHEMBL16914219 | 0.78 | TLR2 (0.44) | TLR2TLR1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910740-B2 | Modulators of amyloid beta | HOFFMANN-LA ROCHE INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2155740-B1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | HOFFMANN LA ROCHE (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-2155740-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. Hoffmann-Roche AG (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138753-A1 | HETARYLANILINES AS MODULATORS FOR AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | F. HOFFMANN-LA ROCHE AG (CH) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280948-A1 | MODULATORS OF AMYLOID BETA | APP, BACE1, BACE2 | PSEN1 7/4885PSEN2 13/4885APH1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.